{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T09:24:57Z","timestamp":1768469097932,"version":"3.49.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,19]]},"DOI":"10.7759\/cureus.76010","type":"journal-article","created":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T15:14:53Z","timestamp":1734621293000},"source":"Crossref","is-referenced-by-count":2,"title":["McArdle Disease: A Diagnostic Challenge Due to Nonspecific Clinical Manifestations"],"prefix":"10.7759","author":[{"given":"Sara","family":"Pereira","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula","family":"Cerqueira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabina","family":"Azevedo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Selmira","family":"Faraldo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/gim.2015.9","article-title":"Determining the prevalence of McArdle disease from gene frequency by analysis of next-generation sequencing data","volume":"17","author":"De Castro M","year":"2015","unstructured":"De Castro M, Johnston J, Biesecker L. Determining the prevalence of McArdle disease from gene frequency by analysis of next-generation sequencing data. Genet Med. 2015, 17:1002-6. 10.1038\/gim.2015.9","journal-title":"Genet Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2009.195040","article-title":"McArdle disease: a clinical review","volume":"81","author":"Quinlivan R","year":"2010","unstructured":"Quinlivan R, Buckley J, James M, et al.. McArdle disease: a clinical review. J Neurol Neurosurg Psychiatry. 2010, 81:1182-8. 10.1136\/jnnp.2009.195040","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2017.04.013","article-title":"Misdiagnosis is an important factor for diagnostic delay in McArdle disease","volume":"27","author":"Scalco RS","year":"2017","unstructured":"Scalco RS, Morrow JM, Booth S, Chatfield S, Godfrey R, Quinlivan R. Misdiagnosis is an important factor for diagnostic delay in McArdle disease. Neuromuscul Disord. 2017, 27:852-5. 10.1016\/j.nmd.2017.04.013","journal-title":"Neuromuscul Disord"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.20344\/amp.19315","article-title":"Valuing mundane manifestations of rare, but underdiagnosed, diseases in Portugal: the example of McArdle disease","volume":"36","author":"Mateus-Pinheiro A","year":"2023","unstructured":"Mateus-Pinheiro A, Costa T, Esperto H, Moreira S. Valuing mundane manifestations of rare, but underdiagnosed, diseases in Portugal: the example of McArdle disease. Acta Med Port. 2023, 36:220-2. 10.20344\/amp.19315","journal-title":"Acta Med Port"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.44701","article-title":"A case report of McArdle disease diagnosed following statin-induced myositis","volume":"15","author":"Teles JS","year":"2023","unstructured":"Teles JS, Ramos CT, Almeida BM, Sousa AV. A case report of McArdle disease diagnosed following statin-induced myositis. Cureus. 2023, 15:e44701. 10.7759\/cureus.44701","journal-title":"Cureus"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20235919","article-title":"McArdle disease: new insights into its underlying molecular mechanisms","volume":"20","author":"Llavero F","year":"2019","unstructured":"Llavero F, Arrazola Sastre A, Luque Montoro M, G\u00e1lvez P, Lacerda HM, Parada LA, Zugaza JL. McArdle disease: new insights into its underlying molecular mechanisms. Int J Mol Sci. 2019, 20:14-6. 10.3390\/ijms20235919","journal-title":"Int J Mol Sci"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2021.10.006","article-title":"Clinical practice guidelines for glycogen storage disease V & VII (McArdle disease and Tarui disease) from an international study group","volume":"31","author":"Lucia A","year":"2021","unstructured":"Lucia A, Martinuzzi A, Nogales-Gadea G, Quinlivan R, Reason S. Clinical practice guidelines for glycogen storage disease V & VII (McArdle disease and Tarui disease) from an international study group. Neuromuscul Disord. 2021, 31:1296-310. 10.1016\/j.nmd.2021.10.006","journal-title":"Neuromuscul Disord"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-020-01562-x","article-title":"Data from the European registry for patients with McArdle disease and other muscle glycogenoses (EUROMAC)","volume":"15","author":"Scalco RS","year":"2020","unstructured":"Scalco RS, Lucia A, Santalla A, et al.. Data from the European registry for patients with McArdle disease and other muscle glycogenoses (EUROMAC). Orphanet J Rare Dis. 2020, 15:330. 10.1186\/s13023-020-01562-x","journal-title":"Orphanet J Rare Dis"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2011-301593","article-title":"Genotypic and phenotypic features of McArdle disease: insights from the Spanish national registry","volume":"83","author":"Lucia A","year":"2012","unstructured":"Lucia A, Ruiz JR, Santalla A, et al.. Genotypic and phenotypic features of McArdle disease: insights from the Spanish national registry. J Neurol Neurosurg Psychiatry. 2012, 83:322-8. 10.1136\/jnnp-2011-301593","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines8020033","article-title":"McArdle disease: clinical, biochemical, histological and molecular genetic analysis of 60 patients","volume":"8","author":"Joshi PR","year":"2020","unstructured":"Joshi PR, Deschauer M, Zierz S. McArdle disease: clinical, biochemical, histological and molecular genetic analysis of 60 patients. Biomedicines. 2020, 8:32-4. 10.3390\/biomedicines8020033","journal-title":"Biomedicines"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2014.08.002","article-title":"PYGM expression analysis in white blood cells: a complementary tool for diagnosing McArdle disease?","volume":"24","author":"de Luna N","year":"2014","unstructured":"de Luna N, Brull A, Lucia A, et al.. PYGM expression analysis in white blood cells: a complementary tool for diagnosing McArdle disease?. Neuromuscul Disord. 2014, 24:1079-86. 10.1016\/j.nmd.2014.08.002","journal-title":"Neuromuscul Disord"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000200914","article-title":"Muscle MRI in McArdle disease: a European multicenter observational study","volume":"99","author":"L\u00f8kken N","year":"2022","unstructured":"L\u00f8kken N, Revsbech KL, Jacobsen LN, et al.. Muscle MRI in McArdle disease: a European multicenter observational study. Neurology. 2022, 99:e1664-75. 10.1212\/WNL.0000000000200914","journal-title":"Neurology"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003458.pub5","article-title":"Pharmacological and nutritional treatment for McArdle disease (glycogen storage disease type V)","volume":"2014","author":"Quinlivan R","year":"2014","unstructured":"Quinlivan R, Martinuzzi A, Schoser B. Pharmacological and nutritional treatment for McArdle disease (glycogen storage disease type V). Cochrane Database Syst Rev. 2014, 2014:CD003458. 10.1002\/14651858.CD003458.pub5","journal-title":"Cochrane Database Syst Rev"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1136\/adc.2008.146548","article-title":"Carbohydrate- and protein-rich diets in McArdle disease: effects on exercise capacity","volume":"79","author":"Andersen ST","year":"2008","unstructured":"Andersen ST, Vissing J. Carbohydrate- and protein-rich diets in McArdle disease: effects on exercise capacity. J Neurol Neurosurg Psychiatry. 2008, 79:1359-63. 10.1136\/adc.2008.146548","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.65.6.786","article-title":"Effect of oral sucrose shortly before exercise on work capacity in McArdle disease","volume":"65","author":"Andersen ST","year":"2008","unstructured":"Andersen ST, Haller RG, Vissing J. Effect of oral sucrose shortly before exercise on work capacity in McArdle disease. Arch Neurol. 2008, 65:786-9. 10.1001\/archneur.65.6.786","journal-title":"Arch Neurol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/ana.20881","article-title":"Aerobic conditioning: an effective therapy in McArdle's disease","volume":"59","author":"Haller RG","year":"2006","unstructured":"Haller RG, Wyrick P, Taivassalo T, Vissing J. Aerobic conditioning: an effective therapy in McArdle's disease. Ann Neurol. 2006, 59:922-8. 10.1002\/ana.20881","journal-title":"Ann Neurol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/9658251","article-title":"Resistance exercise training in McArdle disease: myth or reality?","volume":"2018","author":"Pietrusz A","year":"2018","unstructured":"Pietrusz A, Scalco RS, Quinlivan R. Resistance exercise training in McArdle disease: myth or reality?. Case Rep Neurol Med. 2018, 2018:9658251. 10.1155\/2018\/9658251","journal-title":"Case Rep Neurol Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3390\/biology3010157","article-title":"McArdle disease and exercise physiology","volume":"3","author":"Kitaoka Y","year":"2014","unstructured":"Kitaoka Y. McArdle disease and exercise physiology. Biology (Basel). 2014, 3:157-66. 10.3390\/biology3010157","journal-title":"Biology (Basel)"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.2174\/157016112799305021","article-title":"Statin-induced myotoxicity: pharmacokinetic differences among statins and the risk of rhabdomyolysis, with particular reference to pitavastatin","volume":"10","author":"Catapano AL","year":"2012","unstructured":"Catapano AL. Statin-induced myotoxicity: pharmacokinetic differences among statins and the risk of rhabdomyolysis, with particular reference to pitavastatin. Curr Vasc Pharmacol. 2012, 10:257-67. 10.2174\/157016112799305021","journal-title":"Curr Vasc Pharmacol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.arteri.2018.11.005","article-title":"Treatment of a high cardiovascular risk patient with McArdle's disease with PCSK9 inhibitors","volume":"31","author":"Marco-Bened\u00ed V","year":"2019","unstructured":"Marco-Bened\u00ed V, Jarauta E, P\u00e9rez-Calahorra S, Bea AM, Civeira F. Treatment of a high cardiovascular risk patient with McArdle's disease with PCSK9 inhibitors. Clin Investig Arterioscler. 2019, 31:89-92. 10.1016\/j.arteri.2018.11.005","journal-title":"Clin Investig Arterioscler"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/324503-mcardle-disease-a-diagnostic-challenge-due-to-nonspecific-clinical-manifestations","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T15:14:55Z","timestamp":1734621295000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/324503-mcardle-disease-a-diagnostic-challenge-due-to-nonspecific-clinical-manifestations"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,19]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.76010","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12,19]]}}}